21Dec 2024
Ertugliflozin Reduces Weight in Type 2 Diabetes

Ertugliflozin Reduces Weight in Type 2 Diabetes

This VERTIS CV post hoc analysis assessed ertugliflozin’s effects on weight loss and cardiorenal outcomes by baseline BMI. Among 8246 adults with type 2 diabetes and cardiovascular disease, ertugliflozin led to significant weight reduction at 3 and 5 years. More participants achieved ≥5% and ≥10% weight loss with ertugliflozin versus placebo. No significant differences were observed in the effects on heart failure or kidney outcomes across BMI subgroups. Safety remained consistent with previous data.

  • #endo-diabetology

Like

Save

Share